ReviewNature reviews. Nephrology2012
Diagnosis and treatment of lupus nephritis flares--an update.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Omics-based integrated analysis identified IKZF2 as a biomarker associated with lupus nephritis.Scientific reports · 2022Pooled it
- Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.Rheumatology (Oxford, England) · 2026Trial
- Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.PLoS medicine · 2019Trial
- Measurements of urinary biomarkers at 2 years following a lupus nephritis flare are associated with subsequent renal outcomes.Lupus science & medicine · 2026Article
- Malignancies in lupus nephritis: a retrospective cohort study on epidemiology and risk factors.Lupus science & medicine · 2026Article
- Evolving role of CD8Frontiers in immunology · 2026Review
- Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis.Lupus science & medicine · 2025Article
- Effects of glucocorticoid withdrawal on relapse risk in systemic lupus erythematosus: A systematic review and meta-analysis.iScience · 2025Article
- Serum Albumin as an Early Predictor of Proteinuria Recovery in Lupus Nephritis.Mediterranean journal of rheumatology · 2025Article
- Efficacy and safety of belimumab in lupus nephritis patients with nephrotic syndrome: a single-centre observational retrospective study.Clinical kidney journal · 2025Article
- Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis.Arthritis research & therapy · 2025Article
- Clinical and Laboratory Risk Factors of Early Poor Outcome in Patients With Childhood-Onset Lupus Nephritis-A Single-Center Retrospective Study.Immunity, inflammation and disease · 2025Article
- Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study.Frontiers in immunology · 2025Article
- Telitacicept for systemic lupus erythematosus-associated peripheral neuropathy: a case report.Frontiers in immunology · 2025Article
- Potential of serum sulfatide levels as a marker for classification and disease activity in lupus nephritis.Frontiers in immunology · 2025Article
- A serum biomarker panel and miniarray detection system for tracking disease activity and flare risk in lupus nephritis.Frontiers in immunology · 2025Article
- Predictive value of residual active histologic lesions on renal flare in lupus nephritis patients with clinical remission.Clinical kidney journal · 2024Article
- Exacerbating effects of circadian rhythm disruption on the systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.Nature communications · 2024Article
- Deep learning model to predict lupus nephritis renal flare based on dynamic multivariable time-series data.BMJ open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapses or flares of systemic lupus erythematosus (SLE) are frequent and observed in 27-66% of patients. SLE flares are defined as an increase in disease activity, in general, requiring alternative treatment or intensification of therapy. A renal flare is indicated by an increase in proteinuria and/or serum creatinine concentration, abnormal urine sediment or a reduction in creatinine clearance rate as a result of active disease. The morbidity associated with renal flares is derived from both the kidney damage due to lupus nephritis and treatment-related toxic effects. Current induction treatment protocols achieve remission in the majority of patients with lupus nephritis; however, few studies focus on treatment interventions for renal flares in these patients. The available data, however, suggest that remission can be induced again in a substantial percentage of patients experiencing a lupus nephritis flare. Lupus nephritis flares are independently associated with an increased risk of deterioration in renal function; prevention of renal flares might, therefore, also decrease long-term morbidity and mortality. Appropriate immunosuppressive maintenance therapy might lead to a decrease in the occurrence of renal and extrarenal flares in patients with SLE, and monitoring for the early detection and treatment of renal flares could improve their outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.